Abstract
The non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations can be therapeutically treated by EGFR-TKI such as erlotinib and gefitin......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
